Reply to Reske et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions

Afshar‐Oromieh, Ali; Malcher, A.; Eder, Matthias; Eisenhut, Michael; Linhart, Heinz; Hadaschik, Boris; Holland‐Letz, Tim; Giesel, Frederik L.; Kratochwil, Clemens; Haufe, Sabine; Haberkorn, Uwe; Zechmann, Christian M.

doi:10.1007/s00259-013-2386-y

Cited by 16 publications

(7 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some caution is also warranted, as we have observed an increase in the intensity of radiotracer uptake early after commencing hormone-deprivation therapy, which may result in a "flare" phenomenon seen on PSMA PET images (Fig 11). This observation is supported by preclinical data demonstrating an increase in PSMA expression following androgen-deprivation therapy (59). PSMA PET may also be useful to evaluate response to taxanbased chemotherapy.…”

Section: Restaging Of Metastatic Disease and Theranostic Selectionmentioning

confidence: 67%

Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls

et al. 2018

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is overexpressed in prostate cancer. Radiolabeled small molecules that bind with high affinity to its active extracellular center have emerged as a potential new diagnostic standard of reference for prostate cancer, resulting in images with extraordinary tumor-to-background contrast. Currently, gallium 68 (Ga)-PSMA-11 (or HBED-PSMA) is the most widely used radiotracer for PSMA positron emission tomography (PET)/computed tomography (CT) or PSMA PET/magnetic resonance (MR) imaging. Evolving evidence demonstrates superior sensitivity and specificity of PSMA PET compared to conventional imaging, with frequent identification of subcentimeter prostate cancer lesions. PSMA PET is effective for imaging disease in the prostate, lymph nodes, soft tissue, and bone in a "one-stop-shop" examination. There is emerging evidence for its clinical value in staging of high-risk primary prostate cancer and localization of disease in biochemical recurrence. The high sensitivity provided by PSMA PET, with frequent identification of small-volume disease, is redefining patterns of disease spread compared with those seen at conventional imaging. In metastatic castration-resistant prostate cancer, PSMA PET is frequently used for theranostic selection (eg, lutetium 177-PSMA radionuclide therapy), but its potential use for therapy monitoring is still under debate. However, evidence on its proper use to improve patient-related outcomes, particularly in the setting of early biochemical recurrence and targeted treatment of oligometastatic disease, is still missing. Despite the term prostate specific, PSMA functions as a folate hydrolase and is expressed in a range of normal tissues and in other benign and malignant processes. Knowledge of its physiologic distribution and other causes of uptake is essential to minimize false-positive imaging findings. RSNA, 2018.

show abstract

Section: Restaging Of Metastatic Disease and Theranostic Selectionmentioning

confidence: 67%

Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Biocompatibility test is a key preclinical evaluation of a new drug before application in vivo 20. Herein, hemolysis was conducted as an effective method frequently used for hemocompatibility evaluation.…”

Section: Resultsmentioning

confidence: 99%

Scavenger Receptor-Mediated Targeted Treatment of Collagen-Induced Arthritis by Dextran Sulfate-Methotrexate Prodrug

et al. 2017

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic autoimmune disorder implicated in multiple joint affection and even disability. The activated macrophages perform a predominant role in onset and persistence of RA. Scavenger receptor (SR), one of several receptors overexpressed on the activated macrophages, is a specific biomarker for targeted therapy of numerous chronic inflammation diseases like RA. In this work, dextran sulfate-graft-methotrexate conjugate (DS-g-MTX) is synthesized and characterized, which exhibits excellent targetability to SR on the activated RAW 264.7 cells. Additionally, the enhanced accumulation and potent inflammatory inhibition are observed in the affected joint after intravenous injection of DS-g-MTX, compared to the treatment with dextran-graft-methotrexate (Dex-g-MTX), as is confirmed by the detection of histopathology and pro-inflammatory cytokines. Our work highlights DS-g-MTX as a potential therapeutic option for RA aiming the SR-expressed activated macrophages.

show abstract

“…There is growing recognition of the problem of nonspecific background binding in the initial human trials of PET and SPECT tracers targeting PSMA [28,29].…”

Section: Aff|nity Versus Backgroundmentioning

confidence: 99%

Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker

et al. 2014

View full text Add to dashboard Cite

show abstract

Reply to Reske et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions

Cited by 16 publications

References 2 publications

Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls

Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls

Scavenger Receptor-Mediated Targeted Treatment of Collagen-Induced Arthritis by Dextran Sulfate-Methotrexate Prodrug

Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker

Contact Info

Product

Resources

About